Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.77 USD | -2.80% | +0.10% | -27.84% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.84% | 1.55B | |
-19.90% | 10.81B | |
+50.18% | 3.36B | |
-33.20% | 2.22B | |
-14.31% | 2.16B | |
+22.29% | 1.04B | |
-3.28% | 746M | |
-33.67% | 425M | |
-45.00% | 405M | |
+17.30% | 378M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Needham Adjusts Veracyte's Price Target to $26 From $31 on Peer Multiple Compression, Reiterates Buy Rating